Results 201 to 210 of about 114,856 (264)
Integrative multi‐cohort analyses identify 14‐3‐3γ as a biomarker and regulator of cognitive vulnerability. Experimental studies show that 14‐3‐3γ loss is associated with Tau Thr205 phosphorylation, synaptic dysfunction, and cognitive impairment, while genetic overexpression or pharmacological stabilization of 14‐3‐3γ confers protective effects in ...
Shouqiang Zhu +5 more
wiley +1 more source
Polar lipids modify Alzheimer's Disease pathology by reducing astrocyte pro-inflammatory signaling through platelet-activating factor receptor (PTAFR) modulation. [PDF]
Hans S +8 more
europepmc +1 more source
Leveraging the critical role of glutathione (GSH) in mediating drug resistance and scavenging reactive oxygen species (ROS) in cancer cells, a carrier‐free GSH‐consuming theranostic nanoprodrug, consisting of a BODIPY photosensitizer and the chemotherapeutic drug paclitaxel linked through a GSH‐consuming drug linker, is developed to deeply explore the ...
Hansheng Huang, Binglin Sui
wiley +1 more source
Platelet Activating Factor Receptor and Intercellular Adhesion Molecule-1 Expression Increases in the Small Airway Epithelium and Parenchyma of Patients with Idiopathic Pulmonary Fibrosis: Implications for Microbial Pathogenesis. [PDF]
Shahzad AM +11 more
europepmc +1 more source
Associations between healthy food groups and platelet-activating factor, lipoprotein-associated phospholipase A2 and C-reactive protein: a cross-sectional study. [PDF]
English CJ +5 more
europepmc +1 more source
Platelet activating factor in allergies
The platelet-activating factor (PAF) produced and released by mast cells, basophils, neutrophils, eosinophils, fibroblasts, platelets, endothelial cells, and even cardiac muscle cells plays an important role in inflammatory and thrombotic diseases. PAF has been shown to be an important mediator in anaphylaxis.
Zbigniew Bartuzi
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Platelet-activating factor antagonists
Clinical Reviews in Allergy, 1995The great number of PAF antagonists reviewed in this article clearly shows the tremendous effort made in the last 20 yr to explore the complex biological background of the mechanism of action of PAF and the potential clinical benefit of its antagonists. It is obvious that now highly potent, long-acting, and perorally applicable PAF-receptor antagonists
M, Koltai, P G, Braquet
openaire +4 more sources
Radioimmunoassay for platelet‐activating factor
Lipids, 1991AbstractA radioimmunoassay (RIA) for measurement of platelet‐activating factor (PAF) was developed. At a final antiserum dilution of 1∶640, the lowest detection limit of PAF was 0.1 pmol (50 pg). The standard curve obtained was suitable for measurement of PAF in amounts ranging from 0.1 pmol to 30 pmol. The antiserum showed high specificity.
K, Karasawa +5 more
openaire +2 more sources
Platelet-activating factor receptor
Prostaglandins & Other Lipid Mediators, 2002Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid mediator. Although PAF was named for its potential to induce platelet aggregation, intense investigations have elucidated potent biological actions of PAF in a broad range of cell types and tissues.
Zen-ichiro, Honda +2 more
openaire +3 more sources

